{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T06:28:06Z","timestamp":1793600886244,"version":"4.5.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jaad.2026.02.123","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:21:22Z","timestamp":1773249682000},"page":"e73-e76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reply to Torres et al, \u201cReply to Woodie et al, \u2018Elevated risk of active tuberculosis with interleukin-17, interleukin-23, interleukin-12\/23, Janus kinase inhibitors, cyclosporine, and tumor necrosis factor-\u03b1 inhibitors compared with the general population: A population-based analysis using TriNetX\u2019\u201d"],"prefix":"10.1016","volume":"95","author":[{"given":"Brad R.","family":"Woodie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin A.","family":"Freking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle M.","family":"Rivin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Alan B.","family":"Fleischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2026.02.123_bib1","author":"Torres","year":"2026","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2026.02.123_bib2","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American thoracic Society\/Centers for disease control and Prevention\/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"7","key":"10.1016\/j.jaad.2026.02.123_bib3","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1136\/thoraxjnl-2014-206470","article-title":"Increased risk of mycobacterial infections associated with anti-rheumatic medications","volume":"70","author":"Brode","year":"2015","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.jaad.2026.02.123_bib4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.15585\/mmwr.mm7312a4","article-title":"Tuberculosis \u2014 united States, 2023","volume":"73","author":"Williams","year":"2024","journal-title":"Morb Mortal Wkly Rep"},{"issue":"3","key":"10.1016\/j.jaad.2026.02.123_bib5","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jaad.2025.11.033","volume":"94","author":"Blauvelt","year":"2026","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226003920?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226003920?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:44:58Z","timestamp":1793598298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962226003920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":5,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0190962226003920"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2026.02.123","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reply to Torres et al, \u201cReply to Woodie et al, \u2018Elevated risk of active tuberculosis with interleukin-17, interleukin-23, interleukin-12\/23, Janus kinase inhibitors, cyclosporine, and tumor necrosis factor-\u03b1 inhibitors compared with the general population: A population-based analysis using TriNetX\u2019\u201d","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2026.02.123","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.12.129","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}